Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
TTHI's Cash to Debt is ranked higher than
85% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. TTHI: No Debt )
TTHI' s 10-Year Cash to Debt Range
Min: 4.13   Max: No Debt
Current: No Debt

Interest Coverage No Debt
TTHI's Interest Coverage is ranked higher than
57% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TTHI: No Debt )
TTHI' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 12.89
M-Score: -4.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -112.33
TTHI's ROE (%) is ranked higher than
54% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. TTHI: -112.33 )
TTHI' s 10-Year ROE (%) Range
Min: -66.78   Max: 0.07
Current: -112.33

-66.78
0.07
ROA (%) -94.89
TTHI's ROA (%) is ranked higher than
52% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. TTHI: -94.89 )
TTHI' s 10-Year ROA (%) Range
Min: -55.68   Max: 0.06
Current: -94.89

-55.68
0.06
ROC (Joel Greenblatt) (%) -29738.98
TTHI's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. TTHI: -29738.98 )
TTHI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13626.3   Max: -539.43
Current: -29738.98

-13626.3
-539.43
Revenue Growth (3Y)(%) -100.00
TTHI's Revenue Growth (3Y)(%) is ranked higher than
54% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. TTHI: -100.00 )
TTHI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 91.3
Current: -100

0
91.3
EBITDA Growth (3Y)(%) 80.90
TTHI's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. TTHI: 80.90 )
TTHI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 80.9
Current: 80.9

0
80.9
EPS Growth (3Y)(%) 42.30
TTHI's EPS Growth (3Y)(%) is ranked higher than
95% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. TTHI: 42.30 )
TTHI' s 10-Year EPS Growth (3Y)(%) Range
Min: -100   Max: 51.8
Current: 42.3

-100
51.8
» TTHI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

TTHI Guru Trades in Q1 2014

Jim Simons 131,100 sh (+9.43%)
» More
Q2 2014

TTHI Guru Trades in Q2 2014

Jim Simons 131,300 sh (+0.15%)
» More
Q3 2014

TTHI Guru Trades in Q3 2014

Jim Simons 149,700 sh (+14.01%)
» More
Q4 2014

TTHI Guru Trades in Q4 2014

Jim Simons 175,400 sh (+17.17%)
» More
» Details

Insider Trades

Latest Guru Trades with TTHI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.40
TTHI's P/B is ranked lower than
52% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. TTHI: 12.40 )
TTHI' s 10-Year P/B Range
Min: 0.85   Max: 7.53
Current: 12.4

0.85
7.53
EV-to-EBIT -5.90
TTHI's EV-to-EBIT is ranked higher than
62% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TTHI: -5.90 )
TTHI' s 10-Year EV-to-EBIT Range
Min: -89.7   Max: -0.2
Current: -5.9

-89.7
-0.2
Current Ratio 6.87
TTHI's Current Ratio is ranked higher than
81% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. TTHI: 6.87 )
TTHI' s 10-Year Current Ratio Range
Min: 2.24   Max: 30.83
Current: 6.87

2.24
30.83
Quick Ratio 6.87
TTHI's Quick Ratio is ranked higher than
82% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. TTHI: 6.87 )
TTHI' s 10-Year Quick Ratio Range
Min: 1.66   Max: 30.83
Current: 6.87

1.66
30.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.80
TTHI's Price/Net Cash is ranked higher than
66% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. TTHI: 19.80 )
TTHI' s 10-Year Price/Net Cash Range
Min: 2.13   Max: 64
Current: 19.8

2.13
64
Price/Net Current Asset Value 17.72
TTHI's Price/Net Current Asset Value is ranked higher than
65% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. TTHI: 17.72 )
TTHI' s 10-Year Price/Net Current Asset Value Range
Min: 1.54   Max: 40
Current: 17.72

1.54
40
Price/Tangible Book 17.41
TTHI's Price/Tangible Book is ranked lower than
53% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. TTHI: 17.41 )
TTHI' s 10-Year Price/Tangible Book Range
Min: 1.52   Max: 38.25
Current: 17.41

1.52
38.25
Earnings Yield (Greenblatt) -17.40
TTHI's Earnings Yield (Greenblatt) is ranked lower than
54% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. TTHI: -17.40 )
TTHI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -21.1   Max: 0
Current: -17.4

-21.1
0

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
EPS($) -0.95 -0.28 0.13 0.30
EPS without NRI($) -0.95 -0.28 0.13 0.30

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TTH.Canada, RFYA.Germany,
Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company is a product-focused biopharmaceutical company developing novel therapeutics for disease indications with markets. The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease; TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, Alzheimer's disease, traumatic brain injury, intracerebral haemorrhage, and others, and TT401/402 for the treatment of diabetes. On July 15, 2011, the Company announced that ELND005 Phase 2 clinical trial data would be presented at the International Conference of Alzheimer's Disease (ICAD) meeting on July 18, 2011. Elan and Transition intend to share further detail regarding the Phase 2 data in a peer-reviewed publication.
» More Articles for TTHI

Headlines

Articles On GuruFocus.com
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
Transition Therapeutics Announces Results from Phase 1 AME & Renal Clearance Clinical Studies of... Mar 26 2015
Transition Therapeutics Announces Results from Phase 1 AME & Renal Clearance Clinical Studies of... Mar 26 2015
Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in... Mar 02 2015
Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in... Mar 02 2015
LifeSci Capital Initiates Coverage of Transition Therapeutics Feb 24 2015
Transition Therapeutics to Present at the Cowen and Company 35th Annual Healthcare Conference Feb 19 2015
Transition Therapeutics to Present at the Cowen and Company 35th Annual Healthcare Conference Feb 19 2015
Transition Therapeutics Inc. Announces Closing of Public Offering of US$23 Million of Common Shares Feb 18 2015
Transition Therapeutics Inc. Announces Closing of Public Offering of US$23 Million of Common Shares Feb 18 2015
Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares Feb 12 2015
Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares Feb 12 2015
Transition Therapeutics Inc. Announces Public Offering of Common Shares Feb 11 2015
Transition Therapeutics Inc. Announces Public Offering of Common Shares Feb 11 2015
Transition Therapeutics Announces Second Quarter Fiscal 2015 Financial Results Feb 09 2015
Transition Therapeutics Announces Second Quarter Fiscal 2015 Financial Results Feb 09 2015
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2015 Financial Results on... Feb 05 2015
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2015 Financial Results on... Feb 05 2015
Is Transition Therapeutics (TTHI) Stock a Solid Choice Right Now? Dec 11 2014
Transition Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 08 2014
Transition Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK